Clinical trials: Neuroepithelial Tumor
LGCMN, Large and Giant Congenital Melanocytic Nevi
Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Adolescents and Young Adults
Background: Large and giant congenital melanocytic nevi (LGCMN) are dark birthmarks (moles). They can grow to 8 inches or more across.
- Conditions
- LGCMN, Large and Giant Congenital Melanocytic Nevi, NF1, Solid Tumor
- Trial name
- NCT07891286
- Testing
- Mirdametinib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Glioma
Evaluation of 18F-fluciclovine (FACBC) PET/MR Uptake in Participants With Glioma
This is a pilot study to assess the ability of [F-18]fluciclovine to differentiate pseudoprogression from progression in participants after therapy, at imaging time points within the 12 week interval post chemoradiation.
- Trial name
- FACBC (NCT04114370)
- Testing
- 18F-fluciclovine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- James Mountz
Adult Brain Tumors
Erlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with recurrent glioblastoma…
- Trial name
- NCT00387894
- Testing
- erlotinib hydrochloride
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Michael Prados
Brain Tumor
FBY PET/CT in Patients With Brain Tumors
This study is an open-labeled phase II diagnostic clinical trial to explore the safety and clinical value of FBY in suspected adult brain tumor patients.
- Trial name
- NCT03980431
- Testing
- FBY PET Examination
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking Union Medical College Hospital
Glioma, CNS Tumor, Adult
Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors
This clinical trial is a 2-phase trial designed to evaluate the safety of tarlatamab in combination with a fixed dose of metronomic temozolomide in adolescents and adults with CNS tumors (stratified into two age-based cohorts)…
- Conditions
- Glioma, CNS Tumor, Adult, CNS Tumor, Childhood
- Trial name
- TARLATEM (NCT07243470)
- Testing
- Tarlatamab, Temozolomide (TMZ)
- Where
- 12 sites in France
- Volunteers
- 70 people
- Sponsor
- Centre Leon Berard
Brain and Central Nervous System Tumors
Enzastaurin and Temozolomide in Treating Patients With Primary Gliomas
RATIONALE: Enzastaurin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00516607
- Testing
- enzastaurin hydrochloride, temozolomide, pharmacological study
- Where
- United Kingdom
- Volunteers
- 28 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Glioblastoma Multiforme
A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT
This is a non-randomized, open label, phase I/IIa, dose-escalation study, involving a single injection of Temferon, an investigational advanced therapy consisting of autologous CD34+-enriched hematopoietic stem and progenitor…
- Trial name
- TEM-GBM (NCT03866109)
- Testing
- Temferon
- Where
- 3 sites in Italy
- Volunteers
- 25 people
- Sponsor
- Genenta Science
Osteosarcoma, Ewing Sarcoma
Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
The is a phase II, single arm, open-label, multi-site trial studying the combination of cryoablation therapy and dual checkpoint inhibition with nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) given at the recommended phase 2…
- Conditions
- Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Relapsed Pediatric Solid Tumor
- Trial name
- NCT05302921
- Testing
- Cryoablation Therapy, Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Children's National Research Institute
Rhabdomyosarcomas, Neoplasms, Connective and Soft Tissue
Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse
This is a phase II study to determine the antitumor activity of Vinorelbine and Cyclofosfamide association among patients with refractory tumours or in relapse with rhabdomyosarcomas and other soft tissue tumours, Ewing tumours…
- Conditions
- Rhabdomyosarcomas, Neoplasms, Connective and Soft Tissue, Ewing Tumor, Osteosarcomas
- Trial name
- NCT00180947
- Testing
- Vinorelbine, cyclofosfamide
- Where
- France
- Volunteers
- 210 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Cancer
Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499733
- Testing
- cyclophosphamide, Cryoablation
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recurrent Glioblastoma, CD147 Positive
CD147-CART Cells in Patients With Recurrent Malignant Glioma.
This is a single-center, single-arm, open label and dose escalation clinical study of anti-CD147 CART cells in patients with recurrent malignant glioma.
- Trial name
- NCT04045847
- Testing
- CD147-CART
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Xijing Hospital
Brain and Central Nervous System Tumors
Pharmacologic Study of Methotrexate in Patients Undergoing Stereotactic Biopsy for Recurrent High-Grade Glioma
RATIONALE: Collecting fluid from a brain tumor using a small catheter may help doctors learn how much methotrexate gets into the tumor to kill the tumor cells.
- Trial name
- NCT00463008
- Testing
- methotrexate, pharmacological study
- Volunteers
- 12 people
- Sponsor
- New Approaches to Brain Tumor Therapy Consortium
Neurofibromatosis 2, Vestibular Schwannoma
Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors
In this research study the researchers want to learn more about the effects (both good and bad) the study drug selumetinib has on participants with neurofibromatosis type II (NF2) related tumor.
- Conditions
- Neurofibromatosis 2, Vestibular Schwannoma, Meningioma, Ependymoma
- Trial name
- SEL-TH-1601 (NCT03095248)
- Testing
- Selumetinib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Glioblastoma
A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients
The purpose of the study is to evaluate the feasibility and safety of intra-tumor and interstitial therapy with hBMP4 in increasing doses in patients with progressive and/or multiple recurrent Glioblastoma multiforme (GBM).
- Trial name
- NCT02869243
- Testing
- hrBMP4
- Where
- 4 sites in Israel, Italy and 1 more
- Volunteers
- 15 people
- Sponsor
- Stemgen
Glioblastoma, Glioblastoma Multiforme
Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas
This research is being done to find out if the study drug (ketoconazole) can enter brain tumors at a high enough amount to stop the tumor cells from dividing.
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain, Glioblastoma Multiforme, Adult
- Trial name
- NCT04869449
- Testing
- Ketoconazole
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Milton S. Hershey Medical Center
Brain and Central Nervous System Tumors
Iodine I 131 Monoclonal Antibody TNT-1/B in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody TNT-1/B (^131I MOAB TNT-1/B), can find tumor cells and carry tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00128635
- Testing
- iodine I 131 monoclonal antibody TNT-1/B
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Congenital Hyperinsulinism, Neuroblastoma
18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety
Single centre prospective cohort phase III study of 18F-DOPA PET/CT imaging in specific patient populations: 1. Pediatric patients with congenital hyperinsulinism 2. Pediatric patients with neuroblastoma 3.
- Conditions
- Congenital Hyperinsulinism, Neuroblastoma, Neuroendocrine Tumors, Parkinson Disease
- Trial name
- NCT03042416
- Testing
- 18F-DOPA
- Where
- Canada
- Volunteers
- 400 people
- Sponsor
- University of Alberta
Kidney Cancer, Melanoma (Skin)
Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: Phase II trial to study the effectiveness of radiation therapy in treating patients with newly diagnosed brain metastases from kidney cancer…
- Conditions
- Kidney Cancer, Melanoma (Skin), Metastatic Cancer, Ovarian Cancer
- Trial name
- NCT00003308
- Testing
- stereotactic radiosurgery
- Where
- 14 sites in United States, Australia and 2 more
- Sponsor
- Eastern Cooperative Oncology Group
Head and Neck Cancer
MRI Mapping in Planning Radiation Therapy to the Base of Skull and Brain in Patients With Nonmetastatic Head and Neck Cancer
RATIONALE: Diagnostic procedures, such as specialized types of magnetic resonance imaging (MRI), may help in planning radiation therapy that does less damage to normal tissues.
- Trial name
- NCT00984074
- Testing
- blood-oxygen-level-dependent functional magnetic resonance imaging, diffusion tensor imaging, dynamic contrast-enhanced magnetic resonance imaging
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Glioblastoma Multiforme
Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme
This, international, multi-center, Phase 2 study of verubulin will be conducted in patients with newly diagnosed Glioblastoma Multiforme (GBM). The study will be conducted in two parts.
- Trial name
- NCT01285414
- Testing
- Verubulin, Temozolomide & Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Myrexis Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.